Literature DB >> 29906579

Outcomes of Aggressive Surgical Resection in Growth Hormone-Secreting Pituitary Adenomas with Cavernous Sinus Invasion.

Hun Ho Park1, Eui Hyun Kim2, Cheol Ryong Ku3, Eun Jig Lee3, Sun Ho Kim4.   

Abstract

BACKGROUND: Cavernous sinus (CS) invasion is an unfavorable factor hindering the remission of growth hormone (GH)-secreting pituitary adenomas. Little data exist on aggressive surgical resection, however. We investigated the role of CS exploration for GH-secreting pituitary adenomas with CS invasion.
METHODS: We classified 132 patients with GH-secreting pituitary adenomas invading CS into 4 groups. The patients underwent surgery using a microsurgical transsphenoidal approach (TSA) with endoscopic assistance. Adenomas with CS invasion confined to the medial compartment of the internal carotid artery (ICA) were classified as type A (without radiologic evidence) or type B (with radiologic evidence). Adenomas with ICA encasement were classified according to the surgical approach as type C (standard TSA) or type D (far-lateral TSA). Surgical and endocrinologic outcomes were compared across groups.
RESULTS: For type A, B, C, and D tumors, the rates of gross total resection were 100%, 73.6%, 14.7%, and 0%, respectively, and the rates of endocrinologic remission by surgery alone were 100%, 62.3%, 26.5%, and 0%, respectively. There was no endocrinologic remission by surgery alone for type D tumors; nevertheless, compared with type C tumors, type D tumors showed marked reductions in the postoperative nadir of GH at 1 week, 6 months, and 1 year and of insulin-like growth factor I at 1 year.
CONCLUSIONS: For tumors with CS invasion confined to the medial compartment of the ICA, total resection should be attempted by direct visualization of the entire medial wall of the CS. Even for tumors with ICA encasement, aggressive tumor resection by far-lateral TSA can increase the chance of remission with the help of adjuvant treatment.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cavernous sinus invasion; Gross total resection; Growth hormone–secreting pituitary adenoma

Mesh:

Substances:

Year:  2018        PMID: 29906579     DOI: 10.1016/j.wneu.2018.06.012

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Predictors of postoperative biochemical remission in lower Knosp grade growth hormone-secreting pituitary adenomas: a large single center study.

Authors:  S Zhang; J Chen; Y Zhu; H Wang; Z Mao; S Yao; F Akter; Z Wang; B Hu; D Zhu; C Duan; W Chen
Journal:  J Endocrinol Invest       Date:  2022-09-20       Impact factor: 5.467

Review 2.  Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality?

Authors:  Cheol Ryong Ku; Vladimir Melnikov; Zhaoyun Zhang; Eun Jig Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

3.  Impact of SLC20A1 on the Wnt/β‑catenin signaling pathway in somatotroph adenomas.

Authors:  Jianhua Li; Wei Dong; Zhenye Li; Hongyun Wang; Hua Gao; Yazhuo Zhang
Journal:  Mol Med Rep       Date:  2019-08-06       Impact factor: 2.952

4.  Association of pre- and postoperative αKlotho levels with long-term remission after pituitary surgery for acromegaly.

Authors:  Marian Christoph Neidert; Anna Maria Zeitlberger; Henning Leske; Oliver Tschopp; Lisa Sze; Cornelia Zwimpfer; Peter Wiesli; David Bellut; René-Ludwig Bernays; Elisabeth Jane Rushing; Christoph Schmid
Journal:  Sci Rep       Date:  2022-08-30       Impact factor: 4.996

Review 5.  Advances in Pituitary Surgery.

Authors:  Yoon Hwan Byun; Ho Kang; Yong Hwy Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2022-08-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.